{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:54:23Z","timestamp":1793105663594,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.autrev.2022.103239","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T14:28:16Z","timestamp":1669904896000},"page":"103239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Posterior reversible encephalopathy syndrome and autoimmunity"],"prefix":"10.1016","volume":"22","author":[{"given":"Yang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahm M","family":"Huq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Timilsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Eric","family":"Gershwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2022.103239_bb0005","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103239_bb0010","first-page":"591","article-title":"The reversible posterior cerebral edema syndrome","volume":"19","author":"Dillon","year":"1998","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.autrev.2022.103239_bb0015","first-page":"1199","article-title":"Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions","volume":"21","author":"Casey","year":"2000","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.autrev.2022.103239_bb0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00127893-200201000-00003","article-title":"Hyperperfusion encephalopathies: hypertensive encephalopathy and related conditions","volume":"8","author":"Schwartz","year":"2002","journal-title":"Neurologist"},{"key":"10.1016\/j.autrev.2022.103239_bb0025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/jnnp-2014-310145","article-title":"Clinical outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a multicentric case-control study","volume":"87","author":"Merayo-Chalico","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2022.103239_bb0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00415-011-6152-4","article-title":"The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: the retrospective Berlin PRES study","volume":"259","author":"Liman","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2022.103239_bb0035","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4065\/mcp.2009.0590","article-title":"Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings","volume":"85","author":"Fugate","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2022.103239_bb0040","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/B978-0-444-63599-0.00026-0","article-title":"Posterior reversible encephalopathy in the intensive care unit","volume":"141","author":"Toledano","year":"2017","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.autrev.2022.103239_bb0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2019.07.007","article-title":"Epidemiology, comorbidities, and outcomes of posterior reversible encephalopathy syndrome in children in the United States","volume":"103","author":"Thavamani","year":"2020","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.autrev.2022.103239_bb0050","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1474-4422(15)00111-8","article-title":"Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions","volume":"14","author":"Fugate","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2022.103239_bb0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/WCO.0000000000000640","article-title":"Posterior reversible encephalopathy syndrome","volume":"32","author":"Liman","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.autrev.2022.103239_bb0060","series-title":"Clinical Features, Outcomes and Risk Factors for Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Case-Control Study","first-page":"961","volume":"28","author":"Cui","year":"2019"},{"key":"10.1016\/j.autrev.2022.103239_bb0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/cei.13095","article-title":"Differential serum cytokine profile in patients with systemic lupus erythematosus and posterior reversible encephalopathy syndrome","volume":"192","author":"Merayo-Chalico","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2022.103239_bb0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5414\/NP300771","article-title":"Is posterior reversible encephalopathy syndrome really reversible? Autopsy findings 4.5 years after radiographic resolution","volume":"34","author":"Jacquot","year":"2015","journal-title":"Clin Neuropathol"},{"key":"10.1016\/j.autrev.2022.103239_bb0075","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/acr.22047","article-title":"Clinical features and outcomes of posterior reversible encephalopathy syndrome in patients with systemic lupus erythematosus","volume":"65","author":"Lai","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2022.103239_bb0080","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.autrev.2015.05.006","article-title":"Posterior reversible encephalopathy syndrome--Insight into pathogenesis, clinical variants and treatment approaches","volume":"14","author":"Granata","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103239_bb0085","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/jnnp-2017-316225","article-title":"Controversy of posterior reversible encephalopathy syndrome: what have we learnt in the last 20 years?","volume":"89","author":"Gao","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2022.103239_bb0090","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3174\/ajnr.A0929","article-title":"Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema","volume":"29","author":"Bartynski","year":"2008","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.autrev.2022.103239_bb0095","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.mehy.2014.02.022","article-title":"Posterior reversible encephalopathy syndrome: the endothelial hypotheses","volume":"82","author":"Marra","year":"2014","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.autrev.2022.103239_bb0100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.brainresbull.2017.03.012","article-title":"Immune system activation in the pathogenesis of posterior reversible encephalopathy syndrome","volume":"131","author":"Chen","year":"2017","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.autrev.2022.103239_bb0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11916-020-00932-1","article-title":"Posterior reversible encephalopathy syndrome","volume":"25","author":"Gewirtz","year":"2021","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.autrev.2022.103239_bb0110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnen\/nlx112","article-title":"PRES: review of histological features","volume":"77","author":"Willard","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.autrev.2022.103239_bb0115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/RCT.0b013e3181f31917","article-title":"Posterior reversible encephalopathy syndrome (PRES) with immune system activation, VEGF up-regulation, and cerebral amyloid angiopathy","volume":"35","author":"Kofler","year":"2011","journal-title":"J Comput Assist Tomogr"},{"key":"10.1016\/j.autrev.2022.103239_bb0120","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3174\/ajnr.A1311","article-title":"Reversible encephalopathy after cardiac transplantation: histologic evidence of endothelial activation, T-cell specific trafficking, and vascular endothelial growth factor expression","volume":"30","author":"Horbinski","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.autrev.2022.103239_bb0125","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3174\/ajnr.A4379","article-title":"Cytotoxic edema in posterior reversible encephalopathy syndrome: correlation of MRI features with serum albumin levels","volume":"36","author":"Gao","year":"2015","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.autrev.2022.103239_bb0130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jns.2014.08.035","article-title":"Blood-retina-barrier disruption accompanying blood-brain-barrier dysfunction in posterior reversible encephalopathy syndrome","volume":"346","author":"Ozkan","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2022.103239_bb0135","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00415-015-7928-8","article-title":"Spectrum of cerebral spinal fluid findings in patients with posterior reversible encephalopathy syndrome","volume":"263","author":"Neeb","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2022.103239_bb0140","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.mayocp.2015.07.018","article-title":"Albuminocytologic dissociation in posterior reversible encephalopathy syndrome","volume":"90","author":"Datar","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2022.103239_bb0145","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3389\/fneur.2019.01211","article-title":"Blood-brain barrier disruption as a potential target for therapy in posterior reversible encephalopathy syndrome: evidence from multimodal MRI in rats","volume":"10","author":"Wang","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2022.103239_bb0150","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.03.012","article-title":"Blood-brain barrier breakdown in reduced uterine perfusion pressure: a possible model of posterior reversible encephalopathy syndrome","volume":"23","author":"Porcello Marrone","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.autrev.2022.103239_bb0155","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.autrev.2018.12.004","article-title":"Blood-brain barrier disruption and neuroinflammation as pathophysiological mechanisms of the diffuse manifestations of neuropsychiatric systemic lupus erythematosus","volume":"18","author":"Duarte-Delgado","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103239_bb0160","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/NRL.0000000000000105","article-title":"Chemotherapy-associated posterior reversible encephalopathy syndrome: a case report and review of the literature","volume":"21","author":"How","year":"2016","journal-title":"Neurologist"},{"key":"10.1016\/j.autrev.2022.103239_bb0165","first-page":"1575","article-title":"Elevation of serum lactate dehydrogenase at posterior reversible encephalopathy syndrome onset in chemotherapy-treated cancer patients","volume":"21","author":"Fitzgerald","year":"2014","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"key":"10.1016\/j.autrev.2022.103239_bb0170","doi-asserted-by":"crossref","first-page":"102739","DOI":"10.1016\/j.autrev.2020.102739","article-title":"Posterior reversible encephalopathy syndrome: a neuropsychiatric manifestation of systemic lupus erythematosus","volume":"20","author":"Valdez-L\u00f3pez","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103239_bb0175","series-title":"Arginine Vasopressin and Posterior Reversible Encephalopathy Syndrome Pathophysiology: The Missing Link?","first-page":"6792","volume":"56","author":"Largeau","year":"2019"},{"key":"10.1016\/j.autrev.2022.103239_bb0180","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/bs.vh.2019.08.015","article-title":"Vasopressin and vasopressin receptors in brain edema","volume":"113","author":"Zeynalov","year":"2020","journal-title":"Vitam Horm"},{"key":"10.1016\/j.autrev.2022.103239_bb0185","first-page":"12","article-title":"Posterior reversible encephalopathy syndrome due to hypercalcaemia: a rare cause","author":"Bolanthakodi","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.autrev.2022.103239_bb0190","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.neurol.2016.06.004","article-title":"Posterior reversible encephalopathy syndrome (PRES) and hypomagnesemia: a frequent association?","volume":"172","author":"Chardain","year":"2016","journal-title":"Rev Neurol"},{"key":"10.1016\/j.autrev.2022.103239_bb0195","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.4103\/jfmpc.jfmpc_695_19","article-title":"Hyperglycemia-induced posterior reversible encephalopathy syndrome: a rare cause of reversible blindness","volume":"8","author":"Dev","year":"2019","journal-title":"J Fam Med Prim care"},{"key":"10.1016\/j.autrev.2022.103239_bb0200","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.mehy.2012.11.028","article-title":"Posterior reversible encephalopathy syndrome in the setting of COPD: proposed pathogenesis","volume":"80","author":"Dardis","year":"2013","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.autrev.2022.103239_bb0205","doi-asserted-by":"crossref","first-page":"943914","DOI":"10.1155\/2013\/943914","article-title":"The role of magnesium in the management of cerebral vasospasm","volume":"2013","author":"Odom","year":"2013","journal-title":"Neurol Res Int"},{"key":"10.1016\/j.autrev.2022.103239_bb0210","series-title":"First Reported Case From Australia and Review of Internationally Published Cases Frontiers in neurology","first-page":"600544","article-title":"Case report: posterior reversible leukoencephalopathy syndrome (PRES) as a biologically predictable neurological association in Severe COVID-19","volume":"11","author":"Wijeratne","year":"2020"},{"key":"10.1016\/j.autrev.2022.103239_bb0215","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10067-017-3892-2","article-title":"Clinical features, outcome, and associated factors for posterior reversible encephalopathy in Thai patients with systemic lupus erythematosus: a case-control study","volume":"37","author":"Damrongpipatkul","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103239_bb0220","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1177\/0961203313496341","article-title":"Posterior reversible encephalopathy syndrome in Korean patients with systemic lupus erythematosus: risk factors and clinical outcome","volume":"22","author":"Jung","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2022.103239_bb0225","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3899\/jrheum.101308","article-title":"Posterior reversible encephalopathy syndrome in systemic lupus erythematosus","volume":"38","author":"Varaprasad","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2022.103239_bb0230","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/0961203307078682","article-title":"Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE?","volume":"16","author":"Ishimori","year":"2007","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2022.103239_bb0235","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaut.2016.04.005","article-title":"Autoimmunity, neuroinflammation, pathogen load: a decisive crosstalk in neuropsychiatric SLE","volume":"74","author":"Jeltsch-David","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2022.103239_bb0240","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1177\/0961203316643598","article-title":"Posterior reversible encephalopathy syndrome and association with systemic lupus erythematosus","volume":"25","author":"Ferreira","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2022.103239_bb0245","doi-asserted-by":"crossref","first-page":"e2072","DOI":"10.1212\/WNL.0000000000201086","article-title":"Early readmissions after hospitalization for posterior reversible encephalopathy syndrome","volume":"99","author":"Garg","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2022.103239_bb0250","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s10067-015-3055-2","article-title":"The spectrum of posterior reversible encephalopathy in systemic lupus erythematosus","volume":"34","author":"Budhoo","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103239_bb0255","first-page":"334","article-title":"Posterior reversible encephalopathy syndrome in systemic lupus erythematosus","volume":"19","author":"Gatla","year":"2013","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"key":"10.1016\/j.autrev.2022.103239_bb0260","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.semarthrit.2011.07.001","article-title":"Posterior reversible encephalopathy syndrome: an emerging disease manifestation in systemic lupus erythematosus","volume":"41","author":"Barber","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103239_bb0265","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/0961203313478303","article-title":"Posterior reversible encephalopathy syndrome in systemic lupus erythematosus: pooled analysis of the literature reviews and report of six new cases","volume":"22","author":"Shaharir","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2022.103239_bb0270","first-page":"100","article-title":"Lupus nephritis in Asia: clinical features and management","volume":"1","author":"Yap","year":"2015","journal-title":"Kidney Dis (Basel, Switzerland)"},{"key":"10.1016\/j.autrev.2022.103239_bb0275","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000313","article-title":"Diffuse interstitial brain edema in patients with end-stage renal disease undergoing hemodialysis: a tract-based spatial statistics study","volume":"93","author":"Kong","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2022.103239_bb0280","series-title":"Autoimmune Disease-Associated Hypertension Current Hypertension Reports","first-page":"10","volume":"21","author":"Wolf","year":"2019"},{"key":"10.1016\/j.autrev.2022.103239_bb0285","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3174\/ajnr.A2332","article-title":"Type of edema in posterior reversible encephalopathy syndrome depends on serum albumin levels: an MR imaging study in 28 patients","volume":"32","author":"Pirker","year":"2011","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.autrev.2022.103239_bb0290","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/bc.bc_9_20","article-title":"Blood-transfusion-related posterior reversible encephalopathy syndrome - a description of a new case and review of the literature","volume":"6","author":"Dube","year":"2020","journal-title":"Brain Circ"},{"key":"10.1016\/j.autrev.2022.103239_bb0295","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clineuro.2008.11.017","article-title":"Posterior reversible encephalopathy syndrome as a complication of acute lupus activity","volume":"111","author":"Baizabal-Carvallo","year":"2009","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.autrev.2022.103239_bb0300","first-page":"325657","article-title":"Posterior reversible encephalopathy syndrome due to high dose corticosteroids for an MS relapse","volume":"2015","author":"Morrow","year":"2015","journal-title":"Case Rep Neurol Med"},{"key":"10.1016\/j.autrev.2022.103239_bb0305","article-title":"Posterior reversible encephalopathy syndrome and azathioprine","volume":"6","author":"Vilas-Boas","year":"2019","journal-title":"Eur J Case Rep Intern Med"},{"key":"10.1016\/j.autrev.2022.103239_bb0310","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40264-017-0508-3","article-title":"Anti-angiogenic tyrosine kinase inhibitors and reversible posterior leukoencephalopathy syndrome: could hypomagnesaemia be the trigger?","volume":"40","author":"Shah","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.autrev.2022.103239_bb0315","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000319032","article-title":"Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation","volume":"64","author":"Wu","year":"2010","journal-title":"Eur Neurol"},{"key":"10.1016\/j.autrev.2022.103239_bb0320","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1177\/0961203316644333","article-title":"Differences in disease phenotype and severity in SLE across age groups","volume":"25","author":"Ambrose","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2022.103239_bb0325","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2174\/1567202617666200517110509","article-title":"Association between neutrophil to lymphocyte ratio and malignant brain edema in patients with large hemispheric infarction","volume":"17","author":"Bai","year":"2020","journal-title":"Curr Neurovasc Res"},{"key":"10.1016\/j.autrev.2022.103239_bb0330","doi-asserted-by":"crossref","first-page":"102592","DOI":"10.1016\/j.autrev.2020.102592","article-title":"The immunologic etiology of psychiatric manifestations in systemic lupus erythematosus: a narrative review on the role of the blood brain barrier, antibodies, cytokines and chemokines","volume":"19","author":"Deijns","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103239_bb0335","doi-asserted-by":"crossref","first-page":"674343","DOI":"10.3389\/fimmu.2021.674343","article-title":"Association of circulating vascular endothelial growth factor levels with autoimmune diseases: a systematic review and meta-analysis","volume":"12","author":"Zhan","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103239_bb0340","first-page":"163","article-title":"Posterior reversible encephalopathy syndrome in a patient with chronic obstructive pulmonary disease","volume":"120","author":"Dietvorst","year":"2020","journal-title":"Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"key":"10.1016\/j.autrev.2022.103239_bb0345","series-title":"Interleukin-1 Promotes Autoimmune Neuroinflammation by Suppressing Endothelial Heme Oxygenase-1 at the Blood-Brain Barrier","first-page":"549","volume":"140","author":"Hauptmann","year":"2020"},{"key":"10.1016\/j.autrev.2022.103239_bb0350","first-page":"5574","article-title":"IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program","volume":"177","author":"Argaw","year":"2006","journal-title":"J Immunol (Baltimore, Md\u202f: 1950)"},{"key":"10.1016\/j.autrev.2022.103239_bb0355","first-page":"22","article-title":"Endothelin ET(B) receptor-mediated astrocytic activation: pathological roles in brain disorders","author":"Koyama","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2022.103239_bb0360","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1254\/jphs.09292SC","article-title":"Tumor necrosis factor-alpha mediates the blood-brain barrier dysfunction induced by activated microglia in mouse brain microvascular endothelial cells","volume":"112","author":"Nishioku","year":"2010","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.autrev.2022.103239_bb0365","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1172\/JCI60842","article-title":"Astrocyte-derived VEGF-a drives blood-brain barrier disruption in CNS inflammatory disease","volume":"122","author":"Argaw","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2022.103239_bb0370","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.3389\/fphar.2019.01491","article-title":"Modulation of cytokine-induced astrocytic endothelin-1 production as a possible new approach to the treatment of multiple sclerosis","volume":"10","author":"Hostenbach","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2022.103239_bb0375","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.neuint.2009.11.010","article-title":"IL-1 or TNF receptor gene deletion delays onset of encephalopathy and attenuates brain edema in experimental acute liver failure","volume":"56","author":"B\u00e9meur","year":"2010","journal-title":"Neurochem Int"},{"key":"10.1016\/j.autrev.2022.103239_bb0380","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2018.09.002","article-title":"IL-6: a cytokine at the crossroads of autoimmunity","volume":"55","author":"Jones","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2022.103239_bb0385","doi-asserted-by":"crossref","first-page":"E1289","DOI":"10.1152\/ajpendo.90489.2008","article-title":"Interleukin-6 activates arginine vasopressin neurons in the supraoptic nucleus during immune challenge in rats","volume":"296","author":"Palin","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.autrev.2022.103239_bb0390","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pediatrneurol.2012.08.008","article-title":"Role of interleukin-6 and vascular endothelial growth factor in Henoch-Sch\u00f6nlein purpura with posterior reversible encephalopathy syndrome","volume":"47","author":"Park","year":"2012","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.autrev.2022.103239_bb0395","first-page":"6024","article-title":"Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia","volume":"186","author":"Zhou","year":"2011","journal-title":"J Immunol (Baltimore, Md\u202f: 1950)"},{"key":"10.1016\/j.autrev.2022.103239_bb0400","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1177\/0961203316629556","article-title":"IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus","volume":"25","author":"Yoshio","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2022.103239_bb0405","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3109\/s10165-009-0198-5","article-title":"Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers","volume":"19","author":"Efthimiou","year":"2009","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2022.103239_bb0410","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3899\/jrheum.111124","article-title":"Could increased vascular endothelial growth factor induced by interleukin 17 be the cause of posterior reversible encephalopathy syndrome in systemic lupus erythematosus?","volume":"39","author":"Park","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2022.103239_bb0415","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/s12883-021-02471-7","article-title":"Acute posterior reversible encephalopathy syndrome (PRES) in setting of interferon-beta use: case presentation with reduction of edema in 72h after cessation of interferon-beta therapy with sub-clinical inflammation","volume":"21","author":"Dietz","year":"2021","journal-title":"BMC Neurol"},{"key":"10.1016\/j.autrev.2022.103239_bb0420","doi-asserted-by":"crossref","first-page":"102356","DOI":"10.1016\/j.msard.2020.102356","article-title":"Posterior reversible encephalopathy syndrome, multiple sclerosis and interferon therapy: association, co-incidence or convoluted interplay?","volume":"45","author":"Mastorodemos","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2022.103239_bb0425","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2015.10.003","article-title":"A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus","volume":"15","author":"Ho","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103239_bb0430","first-page":"1003","article-title":"Role of serum autoantibodies in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus","volume":"36","author":"Hirohata","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2022.103239_bb0435","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/WCO.0000000000000810","article-title":"What are the latest clinical findings regarding the association of neurotoxic brain antibodies found in the cerebrospinal fluid in patients with autoimmune disorders?","volume":"33","author":"Arinuma","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.autrev.2022.103239_bb0440","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/mrcr\/rxac029","article-title":"Anti-neutrophil cytoplasmic antibody-associated vasculitis complicated by thrombotic microangiopathy with posterior reversible encephalopathy syndrome successfully treated with eculizumab: a case report","volume":"6","author":"Kitamura","year":"2022","journal-title":"Mod Rheumatol Case Rep"},{"key":"10.1016\/j.autrev.2022.103239_bb0445","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/rheumatology\/keh384","article-title":"Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort","volume":"43","author":"Mikdashi","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103239_bb0450","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000336555","article-title":"Cognitive impairment in systemic lupus erythematosus women with elevated autoantibodies and normal single photon emission computerized tomography","volume":"81","author":"Peretti","year":"2012","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.autrev.2022.103239_bb0455","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.semarthrit.2009.08.004","article-title":"Antiphospholipid syndrome and reversible posterior leukoencephalopathy syndrome","volume":"40","author":"Bandettini di Poggio","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103239_bb0460","first-page":"415","article-title":"Posterior reversible encephalopathy syndrome in systemic lupus erythematosus with anti-phospholipid antibodies treated by plasma exchange: a case report","volume":"15","author":"Maeda","year":"2011","journal-title":"Ther Apher Dial Off Peer Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther"},{"key":"10.1016\/j.autrev.2022.103239_bb0465","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1007\/s00415-014-7406-8","article-title":"Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review","volume":"261","author":"Sciascia","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2022.103239_bb0470","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2377-12-152","article-title":"Posterior reversible encephalopathy syndrome could be an underestimated variant of \u201creversible neurological deficits\u201d in systemic lupus erythematosus","volume":"12","author":"Liu","year":"2012","journal-title":"BMC Neurol"},{"key":"10.1016\/j.autrev.2022.103239_bb0475","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.gore.2017.02.010","article-title":"Posterior reversible encephalopathy syndrome (PRES) associated with ovarian cancer and voltage-gated potassium channel antibodies: a case report","volume":"20","author":"Hadad","year":"2017","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.autrev.2022.103239_bb0480","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/01.wnl.0000343001.36493.ae","article-title":"Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders","volume":"72","author":"Maga\u00f1a","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2022.103239_bb0485","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/24725625.2020.1816640","article-title":"Anti-glomerular basement membrane antibody disease complicated by posterior reversible encephalopathy syndrome","volume":"5","author":"Taniguchi","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"10.1016\/j.autrev.2022.103239_bb0490","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s10875-021-01033-3","article-title":"The innate immune response characterizes posterior reversible encephalopathy syndrome","volume":"41","author":"Nelke","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2022.103239_bb0495","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jns.2014.05.001","article-title":"Blood transfusion-related posterior reversible encephalopathy syndrome","volume":"342","author":"Zhao","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2022.103239_bb0500","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nrneph.2014.102","article-title":"Pre-eclampsia part 1: current understanding of its pathophysiology","volume":"10","author":"Chaiworapongsa","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.autrev.2022.103239_bb0505","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1600-0897.2011.00987.x","article-title":"Increased prevalence of IL-17-producing peripheral blood lymphocytes in pre-eclampsia","volume":"66","author":"Toldi","year":"2011","journal-title":"Am J Reprod Immunol (New York, NY\u202f: 1989)"},{"key":"10.1016\/j.autrev.2022.103239_bb0510","first-page":"2179","article-title":"Posterior reversible encephalopathy syndrome in infection, sepsis, and shock","volume":"27","author":"Bartynski","year":"2006","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.autrev.2022.103239_bb0515","first-page":"915","article-title":"Posterior reversible encephalopathy syndrome (PRES) and infection: a systematic review of the literature","volume":"40","author":"Racchiusa","year":"2019","journal-title":"Case Rep Obstet Gynecol"},{"key":"10.1016\/j.autrev.2022.103239_bb0520","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1053\/j.ajkd.2006.06.004","article-title":"Transient encephalopathy complicating poststreptococcal glomerulonephritis in an adult with diagnostic findings consistent with cerebral vasculitis","volume":"48","author":"Ritt","year":"2006","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"10.1016\/j.autrev.2022.103239_bb0525","first-page":"2035","article-title":"Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes","volume":"55","author":"Chen","year":"2020","journal-title":"Int Med Case Rep J"},{"key":"10.1016\/j.autrev.2022.103239_bb0530","doi-asserted-by":"crossref","DOI":"10.1093\/omcr\/omy046","article-title":"Posterior reversible encephalopathy syndrome in a patient with HIV\/AIDS and immune reconstitution syndrome: a case study and literature review","volume":"2018","author":"Weiss","year":"2018","journal-title":"Oxf Med Case Rep"},{"key":"10.1016\/j.autrev.2022.103239_bb0535","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-221998","article-title":"Posterior reversible encephalopathy syndrome in an HIV-infected patient on antiretroviral treatment: what is the risk factor?","volume":"2018","author":"Birner","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.autrev.2022.103239_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.05.034","article-title":"Posterior reversible encephalopathy syndrome and stroke after intravenous immunoglobulin treatment in Miller-Fisher syndrome\/Bickerstaff brain stem encephalitis overlap syndrome","volume":"23","author":"Stetefeld","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.autrev.2022.103239_bb0545","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11060-016-2078-0","article-title":"Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study","volume":"128","author":"Kamiya-Matsuoka","year":"2016","journal-title":"J Neuro-Oncol"},{"key":"10.1016\/j.autrev.2022.103239_bb0550","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12185-014-1658-z","article-title":"Tumor lysis syndrome as a risk factor for posterior reversible encephalopathy syndrome in children with hematological malignancies","volume":"100","author":"Suzuki","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.autrev.2022.103239_bb0555","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"29","author":"Hottinger","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.autrev.2022.103239_bb0560","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s00415-018-8890-z","article-title":"Severe neurologic complications of immune checkpoint inhibitors: a single-center review","volume":"265","author":"Mancone","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2022.103239_bb0565","first-page":"1329","article-title":"Sickle cell disease and posterior reversible leukoencephalopathy","volume":"21","author":"Geevasinga","year":"2014","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"key":"10.1016\/j.autrev.2022.103239_bb0570","first-page":"249","article-title":"Posterior reversible encephalopathy syndrome in adult sickle-cell patients: case series and literature review","volume":"70","author":"Vargas","year":"2019","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"key":"10.1016\/j.autrev.2022.103239_bb0575","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.semarthrit.2007.10.003","article-title":"Characteristics and outcome of connective tissue diseases in patients with sickle-cell disease: report of 30 cases","volume":"38","author":"Michel","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103239_bb0580","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/rheumatology\/keu482","article-title":"EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres","volume":"54","author":"Pamfil","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103239_bb0585","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1460-9568.2011.07723.x","article-title":"Neutralization of interleukin-1\u03b2 reduces cerebral edema and tissue loss and improves late cognitive outcome following traumatic brain injury in mice","volume":"34","author":"Clausen","year":"2011","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.autrev.2022.103239_bb0590","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1096\/fj.14-258822","article-title":"Anti-IL-6 neutralizing antibody modulates blood-brain barrier function in the ovine fetus","volume":"29","author":"Zhang","year":"2015","journal-title":"FASEB J"},{"key":"10.1016\/j.autrev.2022.103239_bb0595","series-title":"VEGF Signalling Causes Stalls in Brain Capillaries and Reduces Cerebral Blood Flow in Alzheimer\u2019s Mice","first-page":"1449","volume":"145","author":"Ali","year":"2022"},{"key":"10.1016\/j.autrev.2022.103239_bb0600","doi-asserted-by":"crossref","first-page":"9949","DOI":"10.3390\/ijms16059949","article-title":"Pathogenesis of brain edema and investigation into anti-edema drugs","volume":"16","author":"Michinaga","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2022.103239_bb0605","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.brainresbull.2020.10.001","article-title":"Evidence of early vasogenic edema following minor head impact that can be reduced with a vasopressin V1a receptor antagonist","volume":"165","author":"Kulkarni","year":"2020","journal-title":"Brain Res Bull"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222002099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222002099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:26:39Z","timestamp":1761600399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997222002099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":121,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1568997222002099"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103239","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Posterior reversible encephalopathy syndrome and autoimmunity","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103239"}}